Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Subscribe To Our Newsletter & Stay Updated
